Advertisement

Journal of Neurology

, Volume 265, Issue 6, pp 1466–1468 | Cite as

Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis

  • Laura Fionda
  • Fiammetta Vanoli
  • Antonella Di Pasquale
  • Luca Leonardi
  • Stefania Morino
  • Giovanni Antonini
Letter to the Editors

Dear Sirs,

Anti-tumor necrosis factor-alpha (anti-TNF-α) monoclonal antibodies are used in patients with inflammatory bowel disease [1]. Demyelinating neuropathies are increasingly reported among patients treated with these agents [2]. Multifocal motor neuropathy (MMN) is an asymmetric motor neuropathy with multifocal motor conduction blocks, and anti-GM1 antibodies found in 50% of cases [3]. MMN can rarely occur as an adverse event of anti-TNF-α treatment, mainly associated to infliximab [2, 4]. We report a case of a 29-year-old Caucasian man with a 5-year history of ulcerative colitis (UC) in treatment with adalimumab twice monthly. After 6 months of treatment, the patient developed acute left hand weakness spontaneously recovered after 3 weeks. 2 months later, 2 days after adalimumab administration, he presented a new episode of left hand weakness. The neurological examination revealed weakness of left wrist extensors and finger extensors (MRC 3/5), without sensory alterations....

Notes

Compliance with ethical standards

Ethical standards

This letter has been written in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Specific national laws have been observed.

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al (2009) Biologics for rheumatoid arthritis: an overview of cochrane reviews. Cochrane Database Syst Rev 7(4):CD007848Google Scholar
  2. 2.
    Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 257:1421–1431CrossRefPubMedGoogle Scholar
  3. 3.
    Cats EA, Jacobs BC, Yuki N, Tio-Gillen AP, Piepers S, Franssen H et al (2010) Multifocal motor neuropathy association of anti-GM1 IgM antibodies with clinical features. Neurology 75(22):1961–1967CrossRefPubMedGoogle Scholar
  4. 4.
    Barber CE, Lee P, Steinhart AH, Lazarou J (2010) Multifocal motor neuropathy with conduction block following treatment with infliximab. J Rheumatol 37:1778–1780CrossRefPubMedGoogle Scholar
  5. 5.
    Ramos-Casals M, Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D et al (2007) Autoimmune diseases induced by TNF targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86:242–251CrossRefGoogle Scholar
  6. 6.
    Tsouni P, Bill O, Truffert A, Liaudat C, Ochsner F, Steck AJ et al (2015) Anti-TNF alpha medications and neuropathy. J Peripher Nerv Syst 20:397–402CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.AO Sant’AndreaSapienza University of RomeRomeItaly

Personalised recommendations